Aaron M. Carlson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aaron M. Carlson has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Amanda L. Piquet
Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
4 shared publications - Kelli M. Money
Department of Neurology, University of Colorado School of Medicine, Aurora
4 shared publications - Daniel M. Pastula
Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA
3 shared publications - John R. Corboy
Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA
3 shared publications Kavita V. Nair
Department of Neurology University of Colorado School of Medicine Aurora Colorado USA
3 shared publicationsStefan Sillau
Department of Neurology University of Colorado School of Medicine Aurora Colorado USA
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 5 (2) , e200327
Curriculum Innovation: ABCs of Child Neurology
Establishing a foundation of outpatient knowledge is key for child neurology residents as they prepare for careers shaped by evolving diagnostics and treatments. Although national recommendations define core didactic content, strategies for implementation vary widely. To address this gap, educators developed the ABCs of Child Neurology (ABCs), an asynchronous, article-based curriculum grounded in the Master Adaptive Learner framework. On participation, learners will (1) develop competency in outpatient child neurology foundational principles and (2) cultivate self-directed learning behaviors through an asynchronous curriculum. ABCs is mirrored after the American Board of Psychiatry and Neurology (ABPN) Article-Based Continuing Certification program. It comprises 40 modules across 8 core outpatient topics, each featuring a high-yield clinical article and 5-item assessment. The curriculum was implemented during the 2024–2025 academic year for child neurology residents (PGY3–PGY5) at a single institution. Learner expectations include completing 1 module per month and scoring ≥80% on the assessment to receive credit. Evaluation follows the New World Kirkpatrick model, evaluating learner reaction and knowledge growth. Outcomes include module completion rates, aggregate performance on module assessments, and postmodule and postintervention surveys. Descriptive statistics and subgroup analyses by postgraduate year were performed. Ten residents (100%) participated in the pilot. Overall completion rate was 97%, with individual rates ranging from 75% to 107%. Of 129 completed modules, 116 (89.9%) were passed on the first attempt. Mean assessment score was 4.4/5 (SD = 0.8), and median completion time was 43 minutes (IQR-17-470 minutes). Patient care was the most common motivator (41.9%). Postmodule survey ratings revealed 95.7% (mean = 4.5/5; SD = 0.6) of content as essential to practice and 94% (mean = 4.5/5; SD = 0.6) reporting likelihood to apply material. Ratings increased across training levels—PGY-3 = 4.0 (SD = 1.1), PGY-4 = 4.4 (SD = 0.8), and PGY-5 = 4.7 (SD = 0.6) (p = 0.008). Postintervention surveys indicated strong endorsement of the curriculum to colleagues (4.5/5; SD = 0.7; 90% rating 4 or 5). Early work at a single institution supports the feasibility and quality of an asynchronous, article-based curriculum for outpatient child neurology education. Key lessons from the pilot included prioritizing usability to support sustained engagement and aligning content with clinical responsibilities. Future work will evaluate scalability across multiple institutions and explore qualitative insights to optimize integration of asynchronous curricula.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 5 (2) , e200327
Open AccessCurriculum Innovation: ABCs of Child Neurology
Establishing a foundation of outpatient knowledge is key for child neurology residents as they prepare for careers shaped by evolving diagnostics and treatments. Although national recommendations define core didactic content, strategies for implementation vary widely. To address this gap, educators developed the ABCs of Child Neurology (ABCs), an asynchronous, article-based curriculum grounded in the Master Adaptive Learner framework. On participation, learners will (1) develop competency in outpatient child neurology foundational principles and (2) cultivate self-directed learning behaviors through an asynchronous curriculum. ABCs is mirrored after the American Board of Psychiatry and Neurology (ABPN) Article-Based Continuing Certification program. It comprises 40 modules across 8 core outpatient topics, each featuring a high-yield clinical article and 5-item assessment. The curriculum was implemented during the 2024–2025 academic year for child neurology residents (PGY3–PGY5) at a single institution. Learner expectations include completing 1 module per month and scoring ≥80% on the assessment to receive credit. Evaluation follows the New World Kirkpatrick model, evaluating learner reaction and knowledge growth. Outcomes include module completion rates, aggregate performance on module assessments, and postmodule and postintervention surveys. Descriptive statistics and subgroup analyses by postgraduate year were performed. Ten residents (100%) participated in the pilot. Overall completion rate was 97%, with individual rates ranging from 75% to 107%. Of 129 completed modules, 116 (89.9%) were passed on the first attempt. Mean assessment score was 4.4/5 (SD = 0.8), and median completion time was 43 minutes (IQR-17-470 minutes). Patient care was the most common motivator (41.9%). Postmodule survey ratings revealed 95.7% (mean = 4.5/5; SD = 0.6) of content as essential to practice and 94% (mean = 4.5/5; SD = 0.6) reporting likelihood to apply material. Ratings increased across training levels—PGY-3 = 4.0 (SD = 1.1), PGY-4 = 4.4 (SD = 0.8), and PGY-5 = 4.7 (SD = 0.6) (p = 0.008). Postintervention surveys indicated strong endorsement of the curriculum to colleagues (4.5/5; SD = 0.7; 90% rating 4 or 5). Early work at a single institution supports the feasibility and quality of an asynchronous, article-based curriculum for outpatient child neurology education. Key lessons from the pilot included prioritizing usability to support sustained engagement and aligning content with clinical responsibilities. Future work will evaluate scalability across multiple institutions and explore qualitative insights to optimize integration of asynchronous curricula.
- 16 February 2026
- Published by Springer Nature in Medical Science Educator
- Vol. 36 (2) , 839-849
Reviving the Sciences: a Post-clerkship Approach to Required Basic Science Education
Introduction Retention and application of basic science knowledge diminishes as students progress through medical training. Embedding advanced science learning into authentic clinical contexts may strengthen conceptual integration and better prepare students for complex patient care. As many medical schools shorten pre-clerkship curricula, innovative approaches are needed to reinforce and extend basic science learning into the post-clerkship phase. This study aimed to develop, implement, and evaluate the feasibility and student perceptions of a required post-clerkship Advanced Science Course (ASC) curriculum designed to integrate advanced basic and clinical sciences in meaningful, practice-relevant ways. Materials and Methods We implemented four required three-week ASCs within a 13-week semester, redistributing advanced basic and clinical science content from earlier phases and subsequently shortening the pre-clerkship phase. Each ASC combined weekly didactics with related clinical placements. Students completed medical knowledge exams, the NBME Comprehensive Basic Science Examination (CBSE), and course evaluations assessing quality, learning balance, and integration of basic, clinical, and health system science pillars. Feasibility was assessed by faculty and administrative effort (FTEs, time) and by student scheduling practicality. Results The model required ~ 0.4 FTE course director and 1.4 FTE staff support, plus new 12-week clinical placements for 162–184 students annually. Students demonstrated mastery across assessments (79.4% passed all mid-terms, 85.0% finals on first attempt). CBSE equated percent correct scores improved from 50 to 62 overall, with significantly larger gains in ASC-related content areas (M = 15.7, SD = 10.4) than content areas not covered by the ASCs (M = 11.3, SD = 7.5); t(173) = 6.6, p < .01. Students reported high satisfaction in three of four courses, highlighting strong engagement and perceived integration. Conclusions A required post-clerkship ASC model is both feasible and effective for teaching advanced basic science concepts alongside authentic clinical experiences, supporting sustained integration of scientific learning in the post-clerkship phase of medical education.
- 16 February 2026
- Published by Springer Nature in Medical Science Educator
- Vol. 36 (2) , 839-849
Reviving the Sciences: a Post-clerkship Approach to Required Basic Science Education
Introduction Retention and application of basic science knowledge diminishes as students progress through medical training. Embedding advanced science learning into authentic clinical contexts may strengthen conceptual integration and better prepare students for complex patient care. As many medical schools shorten pre-clerkship curricula, innovative approaches are needed to reinforce and extend basic science learning into the post-clerkship phase. This study aimed to develop, implement, and evaluate the feasibility and student perceptions of a required post-clerkship Advanced Science Course (ASC) curriculum designed to integrate advanced basic and clinical sciences in meaningful, practice-relevant ways. Materials and Methods We implemented four required three-week ASCs within a 13-week semester, redistributing advanced basic and clinical science content from earlier phases and subsequently shortening the pre-clerkship phase. Each ASC combined weekly didactics with related clinical placements. Students completed medical knowledge exams, the NBME Comprehensive Basic Science Examination (CBSE), and course evaluations assessing quality, learning balance, and integration of basic, clinical, and health system science pillars. Feasibility was assessed by faculty and administrative effort (FTEs, time) and by student scheduling practicality. Results The model required ~ 0.4 FTE course director and 1.4 FTE staff support, plus new 12-week clinical placements for 162–184 students annually. Students demonstrated mastery across assessments (79.4% passed all mid-terms, 85.0% finals on first attempt). CBSE equated percent correct scores improved from 50 to 62 overall, with significantly larger gains in ASC-related content areas (M = 15.7, SD = 10.4) than content areas not covered by the ASCs (M = 11.3, SD = 7.5); t(173) = 6.6, p < .01. Students reported high satisfaction in three of four courses, highlighting strong engagement and perceived integration. Conclusions A required post-clerkship ASC model is both feasible and effective for teaching advanced basic science concepts alongside authentic clinical experiences, supporting sustained integration of scientific learning in the post-clerkship phase of medical education.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (5) , e200510
Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill Adults
The presence of oligoclonal bands (OCBs) indicates an augmented immune response within the CNS and is integral to the diagnosis of multiple sclerosis (MS). Expert consensus panels recommend OCB testing for conditions other than MS, despite limited data to suggest diagnostic value. Our objectives were to evaluate the spectrum of disease etiologies associated with OCBs and determine the accuracy of OCBs in identifying autoimmune disorders affecting the CNS. This is a retrospective, observational, single health system study that captured all patients in acute care settings who underwent OCB testing from January 1, 2018, through December 31, 2020. Patient diagnoses and diagnostic categories were adjudicated by clinicians. Test accuracy characteristics to detect CNS autoimmune disorders were computed by comparing 2 or more OCBs as a positive index test against target disease etiologies as reference standards. OCB testing was performed across all etiologies in 926 patients; 78 patients had MS, and 148 had CNS autoimmune disorders not related to MS. Oligoclonal bands exhibited high sensitivity for MS but low sensitivity and low predictive power for other CNS autoimmune disorders. In contrast to their diagnostic accuracy in MS, OCBs exhibited limited discriminatory power in the detection of other autoimmune disorders affecting the CNS. Beyond suspected MS, OCBs should not be relied on as an accurate diagnostic tool because a positive result can manifest in an array of neurologic diseases and a negative result does not exclude an autoimmune etiology.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (5) , e200510
Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill Adults
The presence of oligoclonal bands (OCBs) indicates an augmented immune response within the CNS and is integral to the diagnosis of multiple sclerosis (MS). Expert consensus panels recommend OCB testing for conditions other than MS, despite limited data to suggest diagnostic value. Our objectives were to evaluate the spectrum of disease etiologies associated with OCBs and determine the accuracy of OCBs in identifying autoimmune disorders affecting the CNS. This is a retrospective, observational, single health system study that captured all patients in acute care settings who underwent OCB testing from January 1, 2018, through December 31, 2020. Patient diagnoses and diagnostic categories were adjudicated by clinicians. Test accuracy characteristics to detect CNS autoimmune disorders were computed by comparing 2 or more OCBs as a positive index test against target disease etiologies as reference standards. OCB testing was performed across all etiologies in 926 patients; 78 patients had MS, and 148 had CNS autoimmune disorders not related to MS. Oligoclonal bands exhibited high sensitivity for MS but low sensitivity and low predictive power for other CNS autoimmune disorders. In contrast to their diagnostic accuracy in MS, OCBs exhibited limited discriminatory power in the detection of other autoimmune disorders affecting the CNS. Beyond suspected MS, OCBs should not be relied on as an accurate diagnostic tool because a positive result can manifest in an array of neurologic diseases and a negative result does not exclude an autoimmune etiology.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200489
West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies
The literature on severe West Nile virus (WNV) neuroinvasive disease (WNND) in patients treated with anti-CD20 therapies is limited. We systematically characterize cases of WNND in the tertiary academic UCHealth system. A retrospective cohort (January 2016 to January 2024) of patients with a validated diagnosis of WNND and anti-CD20 medication use was identified with electronic medical record query followed by individual chart review. We identified 25 patients; multiple sclerosis was the most common indication for anti-CD20 therapy in 13 patients (52%). Twenty-one patients (84%) presented with meningoencephalitis. CSF WNV IgM was positive in 5 of 21 patients (24%) who were tested while 13 of 14 tested patients (93%) had positive reverse-transcription PCR (RT-PCR) findings in the CSF. MRI demonstrated anomalies associated with WNND in 12 of 23 patients (52%) with available imaging. Intensive care unit admission was required in 8 patients (32%), and 12 patients (48%) were treated with intravenous immunoglobulin. Worsening of ≥1 point from pre-WNV baseline modified Rankin Scale (mRS) score to the 90-day postdischarge mRS score was seen in 18 patients (75%). Two patients (8%) died by 90 days. WNND leads to disability accrual in patients on B cell-depleting anti-CD20 therapies. Utilization of RT-PCR is important in optimizing diagnosis in this patient population because of limited sensitivity of the WNV-IgM testing commonly used in the general population.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200489
West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies
The literature on severe West Nile virus (WNV) neuroinvasive disease (WNND) in patients treated with anti-CD20 therapies is limited. We systematically characterize cases of WNND in the tertiary academic UCHealth system. A retrospective cohort (January 2016 to January 2024) of patients with a validated diagnosis of WNND and anti-CD20 medication use was identified with electronic medical record query followed by individual chart review. We identified 25 patients; multiple sclerosis was the most common indication for anti-CD20 therapy in 13 patients (52%). Twenty-one patients (84%) presented with meningoencephalitis. CSF WNV IgM was positive in 5 of 21 patients (24%) who were tested while 13 of 14 tested patients (93%) had positive reverse-transcription PCR (RT-PCR) findings in the CSF. MRI demonstrated anomalies associated with WNND in 12 of 23 patients (52%) with available imaging. Intensive care unit admission was required in 8 patients (32%), and 12 patients (48%) were treated with intravenous immunoglobulin. Worsening of ≥1 point from pre-WNV baseline modified Rankin Scale (mRS) score to the 90-day postdischarge mRS score was seen in 18 patients (75%). Two patients (8%) died by 90 days. WNND leads to disability accrual in patients on B cell-depleting anti-CD20 therapies. Utilization of RT-PCR is important in optimizing diagnosis in this patient population because of limited sensitivity of the WNV-IgM testing commonly used in the general population.
- Open Access
- 24 December 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e210078
Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System
Stiff person syndrome spectrum disorder (SPSD) is a rare autoimmune disorder characterized by progressive muscle stiffness and painful spasms with an estimated prevalence of 1–2 cases per million people. Population-based epidemiologic studies are lacking because of both poor patient capture and the lack of standardized diagnostic criteria. Objectives of this study were to describe the incidence and prevalence of SPSD within the University of Colorado Health (UCH) system and apply previously proposed published criteria for SPSD within this population. We queried Health Data Compass, an electronic health data repository for a large academic health care system, from 2012 through 2022 for all patients older than 18 years with International Classification of Diseases, 10th Revision (ICD-10) codes pertaining to stiff person syndrome. Records were reviewed for diagnostic confirmation. We calculated yearly and period prevalence and incidence rates based on observable person-time exposure of our cohort. We applied previously published Mayo Clinic and Johns Hopkins criteria for SPSD and compared period prevalence based on each criterion and evaluated for agreement. Two hundred and seventy-three patients met the initial inclusion criteria using ICD-10 codes; 59 were confirmed to have SPSD. The mean age was 49.7 years (SD = 12.9), 59.3% were female, 59.3% were considered antibody positive. The total database population over the interval was 2,801,674 persons. The estimated prevalence of SPSD based on our UCH cohort was 2.11 (95% CI 1.57–2.64) per 100,000 persons. The average yearly incidence was 0.35 per 100,000 person-years (95% CI 0.27–0.46). Applying different clinical diagnostic criteria, the estimated prevalence ranged from 1.36 (95% CI 0.93–1.79) to 1.82 (95% CI 1.32–2.32) per 100,000 persons. We describe a prevalence of SPSD of 2.11 per 100,000 persons in our UCH cohort. Prevalence estimates differed depending on which clinical diagnostic criteria were applied and whether possible SPSD cases were included. Using the most stringent criteria for diagnosis, we report a prevalence of 1.36 per 100,000 persons. While our study uniquely captures many US demographic groups, limitations remain because this is a retrospective review of a single system. Additional studies are needed to determine whether these results are representative of a national or global population.
- 24 December 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e210078
Open AccessPopulation-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System
Stiff person syndrome spectrum disorder (SPSD) is a rare autoimmune disorder characterized by progressive muscle stiffness and painful spasms with an estimated prevalence of 1–2 cases per million people. Population-based epidemiologic studies are lacking because of both poor patient capture and the lack of standardized diagnostic criteria. Objectives of this study were to describe the incidence and prevalence of SPSD within the University of Colorado Health (UCH) system and apply previously proposed published criteria for SPSD within this population. We queried Health Data Compass, an electronic health data repository for a large academic health care system, from 2012 through 2022 for all patients older than 18 years with International Classification of Diseases, 10th Revision (ICD-10) codes pertaining to stiff person syndrome. Records were reviewed for diagnostic confirmation. We calculated yearly and period prevalence and incidence rates based on observable person-time exposure of our cohort. We applied previously published Mayo Clinic and Johns Hopkins criteria for SPSD and compared period prevalence based on each criterion and evaluated for agreement. Two hundred and seventy-three patients met the initial inclusion criteria using ICD-10 codes; 59 were confirmed to have SPSD. The mean age was 49.7 years (SD = 12.9), 59.3% were female, 59.3% were considered antibody positive. The total database population over the interval was 2,801,674 persons. The estimated prevalence of SPSD based on our UCH cohort was 2.11 (95% CI 1.57–2.64) per 100,000 persons. The average yearly incidence was 0.35 per 100,000 person-years (95% CI 0.27–0.46). Applying different clinical diagnostic criteria, the estimated prevalence ranged from 1.36 (95% CI 0.93–1.79) to 1.82 (95% CI 1.32–2.32) per 100,000 persons. We describe a prevalence of SPSD of 2.11 per 100,000 persons in our UCH cohort. Prevalence estimates differed depending on which clinical diagnostic criteria were applied and whether possible SPSD cases were included. Using the most stringent criteria for diagnosis, we report a prevalence of 1.36 per 100,000 persons. While our study uniquely captures many US demographic groups, limitations remain because this is a retrospective review of a single system. Additional studies are needed to determine whether these results are representative of a national or global population.
- Open Access
- 21 December 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (1) , 169-179
The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population
Objective: To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system.Methods: We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin‐4 IgG test or (2) any G36 ICD‐10 code. We extracted key clinical elements by chart review and confirmed diagnosis by the 2015 International Panel for NMO Diagnosis criteria. Annual incidence and prevalence rates were calculated.Results: Our population consisted of 2,475,591 individuals contributing 11,103,522.72 person‐years of observation. In total, 115 seropositive NMOSD patients were identified. The average yearly incidence was 0.22 per 100,000 person‐years. Age and sex‐adjusted prevalence (per 100,000) was 4.33, and highest among those identifying as Asian or Pacific Islander (17.72), and Black (14.74), as separately by Hispanic ethnicity (8.02). Prevalence was higher in women (6.20:1 female:male ratio). Transverse myelitis (45%) and optic neuritis (43%) were the most common presenting clinical syndromes. In total, 6% of initial presentations were characterized by short‐segment transverse myelitis without other features.Interpretation: Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short‐segment myelitis underscores the need for serum aquaporin‐4 IgG testing in acute myelitis presentations.
- 21 December 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (1) , 169-179
Open AccessThe epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population
Objective: To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system.Methods: We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin‐4 IgG test or (2) any G36 ICD‐10 code. We extracted key clinical elements by chart review and confirmed diagnosis by the 2015 International Panel for NMO Diagnosis criteria. Annual incidence and prevalence rates were calculated.Results: Our population consisted of 2,475,591 individuals contributing 11,103,522.72 person‐years of observation. In total, 115 seropositive NMOSD patients were identified. The average yearly incidence was 0.22 per 100,000 person‐years. Age and sex‐adjusted prevalence (per 100,000) was 4.33, and highest among those identifying as Asian or Pacific Islander (17.72), and Black (14.74), as separately by Hispanic ethnicity (8.02). Prevalence was higher in women (6.20:1 female:male ratio). Transverse myelitis (45%) and optic neuritis (43%) were the most common presenting clinical syndromes. In total, 6% of initial presentations were characterized by short‐segment transverse myelitis without other features.Interpretation: Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short‐segment myelitis underscores the need for serum aquaporin‐4 IgG testing in acute myelitis presentations.
- Open Access
- 23 April 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (6) , 1526-1534
Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population
ObjectiveOur objectives were to (1) obtain the prevalence and demography of people with multiple sclerosis (MS) in a representative Colorado population, and (2) to assess the utilization of disease-modifying therapy within this prevalent cohort.MethodsThis is a retrospective, observational study of patients that had contact with the University of Colorado Health System from 2012 to 2020. We queried Health Data Compass, a data warehouse, for patient data and applied the MS Prevalence Workgroup Algorithm to generate a prevalent cohort. We calculated prevalence as of 31 December 2020, and stratified by age, sex, race, and ethnicity. Payer information and treatment exposure were obtained from linked claims from the Colorado All Payers Claim Database. Disease-modifying therapies were classified as highly effective and moderately effective based on the clinical trial, TREAT-MS (NCT03500328).ResultsFrom a population of 1,382,821 individuals, 8557 people with MS were captured. Age-adjusted prevalence of MS as of 31 December 2020 was 572.3 per 100,000 with a mean age of 47.36. Prevalence varied between demographic subgroups, with the lowest prevalence in Hispanic men (215.6) and highest in White (824.1) and Black women (820.1). Overall disease-modifying therapy exposure was 62.4%, with increased highly effective therapy use and a corresponding decrease in moderately effective therapy use on a yearly basis.InterpretationMS is highly prevalent in a representative Colorado cohort. Overall treatment and proportion of highly effective therapy exposure increased significantly during a critical period of MS therapeutic advances, indicating a shift in disease management driven sharply by the availability of on-label anti-CD20 therapy.
- 23 April 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (6) , 1526-1534
Open AccessShifting patterns of multiple sclerosis treatment in a highly prevalent United States population
ObjectiveOur objectives were to (1) obtain the prevalence and demography of people with multiple sclerosis (MS) in a representative Colorado population, and (2) to assess the utilization of disease-modifying therapy within this prevalent cohort.MethodsThis is a retrospective, observational study of patients that had contact with the University of Colorado Health System from 2012 to 2020. We queried Health Data Compass, a data warehouse, for patient data and applied the MS Prevalence Workgroup Algorithm to generate a prevalent cohort. We calculated prevalence as of 31 December 2020, and stratified by age, sex, race, and ethnicity. Payer information and treatment exposure were obtained from linked claims from the Colorado All Payers Claim Database. Disease-modifying therapies were classified as highly effective and moderately effective based on the clinical trial, TREAT-MS (NCT03500328).ResultsFrom a population of 1,382,821 individuals, 8557 people with MS were captured. Age-adjusted prevalence of MS as of 31 December 2020 was 572.3 per 100,000 with a mean age of 47.36. Prevalence varied between demographic subgroups, with the lowest prevalence in Hispanic men (215.6) and highest in White (824.1) and Black women (820.1). Overall disease-modifying therapy exposure was 62.4%, with increased highly effective therapy use and a corresponding decrease in moderately effective therapy use on a yearly basis.InterpretationMS is highly prevalent in a representative Colorado cohort. Overall treatment and proportion of highly effective therapy exposure increased significantly during a critical period of MS therapeutic advances, indicating a shift in disease management driven sharply by the availability of on-label anti-CD20 therapy.
- 7 March 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 459, 122946
Diversity, equity, and inclusion (DEI) in medical education: DEI at the bedside
- 7 March 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 459, 122946
Diversity, equity, and inclusion (DEI) in medical education: DEI at the bedside
- 8 January 2024
- Published by Wiley in Journal of Dental Education
- Vol. 88, 1938-1941
An innovative 3D‐printed model of the cerebral arterial circle for dental gross anatomy
- 8 January 2024
- Published by Wiley in Journal of Dental Education
- Vol. 88, 1938-1941
An innovative 3D‐printed model of the cerebral arterial circle for dental gross anatomy
- 21 November 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 14 (2) , 189-194
Anti-NMDA Receptor Encephalitis Related to Renal Cell Carcinoma: A Case Report
Anti-NMDA receptor (NMDAR) encephalitis is characterized by a well-defined neuropsychiatric syndrome and CSF antibodies against the GluN1 subunit of the NMDAR. 40% of cases are related to underlying tumors, the vast majority ovarian teratomas (94%). We report a case of anti-NMDAR encephalitis associated with renal cell carcinoma (RCC). A 20-year-old female presented to the ED with behavioral changes, involuntary movements, tachycardia, and alternating obtundation with agitation which progressed over 3 weeks. Involuntary movements were severe, requiring intubation and sedation for control, and were accompanied by rhabdomyolysis. Brain MRI showed bilateral mesiotemporal T2/FLAIR hyperintensities. Anti-NMDAR antibodies were present in the serum (1:640) and CSF (1:320). Malignancy screening revealed a renal mass concerning for RCC, which was confirmed upon resection. She was started on high dose IV methylprednisolone and plasmapheresis, followed by rituximab. Lack of response led to escalating immunotherapy with cyclophosphamide. Clinical course was complicated by prolonged ICU admission, prolonged sedation, severe dysautonomia and bacteremia. Improvement began 2 months after immunotherapy, and she was discharged to rehabilitation 100 days after admission with mild neuropsychiatric symptoms. Repeat malignancy screenings, including whole-body imaging and transvaginal ultrasound were consistently negative. Herein, we describe a case of definite anti-NMDAR encephalitis in the setting of newly diagnosed RCC. This case illustrates how tumors other than ovarian teratomas may act as immunological triggers, as well as the complex and prolonged symptomatic and immunosuppressive therapies required in severe presentations of anti-NMDAR encephalitis.
- 21 November 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 14 (2) , 189-194
Anti-NMDA Receptor Encephalitis Related to Renal Cell Carcinoma: A Case Report
Anti-NMDA receptor (NMDAR) encephalitis is characterized by a well-defined neuropsychiatric syndrome and CSF antibodies against the GluN1 subunit of the NMDAR. 40% of cases are related to underlying tumors, the vast majority ovarian teratomas (94%). We report a case of anti-NMDAR encephalitis associated with renal cell carcinoma (RCC). A 20-year-old female presented to the ED with behavioral changes, involuntary movements, tachycardia, and alternating obtundation with agitation which progressed over 3 weeks. Involuntary movements were severe, requiring intubation and sedation for control, and were accompanied by rhabdomyolysis. Brain MRI showed bilateral mesiotemporal T2/FLAIR hyperintensities. Anti-NMDAR antibodies were present in the serum (1:640) and CSF (1:320). Malignancy screening revealed a renal mass concerning for RCC, which was confirmed upon resection. She was started on high dose IV methylprednisolone and plasmapheresis, followed by rituximab. Lack of response led to escalating immunotherapy with cyclophosphamide. Clinical course was complicated by prolonged ICU admission, prolonged sedation, severe dysautonomia and bacteremia. Improvement began 2 months after immunotherapy, and she was discharged to rehabilitation 100 days after admission with mild neuropsychiatric symptoms. Repeat malignancy screenings, including whole-body imaging and transvaginal ultrasound were consistently negative. Herein, we describe a case of definite anti-NMDAR encephalitis in the setting of newly diagnosed RCC. This case illustrates how tumors other than ovarian teratomas may act as immunological triggers, as well as the complex and prolonged symptomatic and immunosuppressive therapies required in severe presentations of anti-NMDAR encephalitis.